目的 探讨尿毒清颗粒联合非布司他治疗高尿酸血症的临床疗效。方法 选取2014年3月—2016年3月在驻马店市中心医院治疗的高尿酸血症患者140例，随机分为对照组（70例）和治疗组（70例）。对照组患者口服非布司他片，40 mg/次，1次/d；治疗组在对照组基础上口服尿毒清颗粒，5 g/次，4次/d。两组患者均经过12周治疗。观察两组患者临床疗效，比较治疗前后两组患者血清黄嘌呤氧化酶（XOD）、尿酸（BUA）、血肌酐（Scr）、尿素氮（BUN）、血清炎性因子水平以及血清NO和ET-1水平。结果 对照组临床总有效率为87.14%，显著低于治疗组的97.14%，两组比较差异具有统计学意义（P<0.05）。治疗后，两组患者血清XOD、BUA、Scr、BUN水平均明显降低（P<0.05）；且治疗组比对照组降低的更明显（P<0.05）。治疗后，两组患者血清白细胞介素-1β（IL-1β）、髓过氧化物酶（MPO）、可溶性细胞间黏附分子-1（sICAM-1）、肿瘤坏死因子-α（TNF-α）水平均明显降低（P<0.05）；且治疗组患者血清炎性因子水平明显低于对照组（P<0.05）。治疗后，两组患者血清NO水平显著升高，内皮素-1（ET-1）水平显著降低，同组比较差异具有统计学意义（P<0.05）；且治疗组患者NO和ET-1水平明显优于对照组（P<0.05）。结论 尿毒清颗粒联合非布司他治疗高尿酸血症可有效降低机体炎症反应，改善血管内皮功能，具有一定的临床推广应用价值。

Objective To investigate the clinical efficacy of Niaoduqing Granules combined with febuxostat in treatment of hyperuricemia. Methods Patients (140 cases) with hyperuricemia in Zhumadian Central Hospital from March 2014 to March 2016 were randomly divided into control (70 cases) and treatment (70 cases) groups. Patients in the control group were po administered with Febuxostat Tablets, 40 mg/time, once daily. Patients in the treatment group were po administered with Niaoduqing Granules on the basis of the control group, 5 g/time, four times daily. Patients in two groups were treated for 12 weeks. After treatment, the clinical efficacy was evaluated, and the serum XOD, BUA, Scr, BUN, serum inflammatory factors, serum NO and ET-1 levels in two groups before and after treatment were compared. Results After treatment, the clinical efficacy in the control group was 87.14%, which was significantly lower than 97.14% in the treatment group, and there were differences between two groups (P < 0.05). After treatment, the XOD, BUA, Scr and BUN levels in two groups were significantly decreased (P < 0.05). And these indexes level in the treatment group decreased more significantly than that in the control group (P < 0.05). After treatment, the IL-1β, MPO, sICAM-1 and TNF-α levels in two groups were significantly decreased (P < 0.05). And the serum inflammatory factors in the treatment group were significantly lower than those in the control group (P < 0.05). After treatment, the serum NO level in two groups was significantly increased, but ET-1 level was significantly decreased, and the difference was statistically significant in the same group (P < 0.05). And serum NO and ET-1 level in the treatment group was significantly better than that in the control group (P < 0.05). Conclusion Niaoduqing Granules combined with febuxostat in treatment of hyperuricemia can effectively reduce the inflammatory reaction and improve the vascular endothelial function, which has a certain clinical application value.